AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $242.25 billion. The enterprise value is $268.70 billion.
| Market Cap | 242.25B |
| Enterprise Value | 268.70B |
Important Dates
The last earnings date was Thursday, July 25, 2024, before market open.
| Earnings Date | Jul 25, 2024 |
| Ex-Dividend Date | Feb 22, 2024 |
Share Statistics
AstraZeneca has 3.10 billion shares outstanding.
| Shares Outstanding | 3.10B |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 16.88% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 38.21 and the forward PE ratio is 16.31. AstraZeneca's PEG ratio is 0.89.
| PE Ratio | 38.21 |
| Forward PE | 16.31 |
| PS Ratio | 4.93 |
| Forward PS | 4.36 |
| PB Ratio | 6.13 |
| P/FCF Ratio | 25.55 |
| PEG Ratio | 0.89 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.44, with an EV/FCF ratio of 28.34.
| EV / Earnings | 41.72 |
| EV / Sales | 5.47 |
| EV / EBITDA | 18.44 |
| EV / EBIT | 28.50 |
| EV / FCF | 28.34 |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 0.85.
| Current Ratio | 0.89 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | 2.30 |
| Debt / FCF | 3.54 |
| Interest Coverage | 5.59 |
Financial Efficiency
Return on equity (ROE) is 16.80% and return on invested capital (ROIC) is 10.31%.
| Return on Equity (ROE) | 16.80% |
| Return on Assets (ROA) | 6.40% |
| Return on Capital (ROIC) | 10.31% |
| Revenue Per Employee | $546,529 |
| Profits Per Employee | $71,635 |
| Employee Count | 89,900 |
| Asset Turnover | 0.49 |
| Inventory Turnover | 1.64 |
Taxes
In the past 12 months, AstraZeneca has paid $1.30 billion in taxes.
| Income Tax | 1.30B |
| Effective Tax Rate | 16.81% |
Stock Price Statistics
The stock price has increased by +12.61% in the last 52 weeks. The beta is 0.15, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +12.61% |
| 50-Day Moving Average | 78.49 |
| 200-Day Moving Average | 69.79 |
| Relative Strength Index (RSI) | 48.30 |
| Average Volume (20 Days) | 3,608,883 |
Short Selling Information
| Short Interest | 5.80M |
| Short Previous Month | 6.41M |
| Short % of Shares Out | 0.27% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.87 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $49.13 billion and earned $6.44 billion in profits. Earnings per share was $2.07.
| Revenue | 49.13B |
| Gross Profit | 40.33B |
| Operating Income | 9.05B |
| Pretax Income | 7.74B |
| Net Income | 6.44B |
| EBITDA | 14.57B |
| EBIT | 9.43B |
| Earnings Per Share (EPS) | $2.07 |
Balance Sheet
The company has $7.08 billion in cash and $33.53 billion in debt, giving a net cash position of -$26.46 billion or -$8.53 per share.
| Cash & Cash Equivalents | 7.08B |
| Total Debt | 33.53B |
| Net Cash | -26.46B |
| Net Cash Per Share | -$8.53 |
| Equity (Book Value) | 39.51B |
| Book Value Per Share | 12.74 |
| Working Capital | -3.17B |
Cash Flow
In the last 12 months, operating cash flow was $11.07 billion and capital expenditures -$1.58 billion, giving a free cash flow of $9.48 billion.
| Operating Cash Flow | 11.07B |
| Capital Expenditures | -1.58B |
| Free Cash Flow | 9.48B |
| FCF Per Share | $3.06 |
Margins
Gross margin is 82.08%, with operating and profit margins of 18.42% and 13.11%.
| Gross Margin | 82.08% |
| Operating Margin | 18.42% |
| Pretax Margin | 15.76% |
| Profit Margin | 13.11% |
| EBITDA Margin | 29.66% |
| EBIT Margin | 19.19% |
| FCF Margin | 19.30% |
Dividends & Yields
This stock pays an annual dividend of $1.45, which amounts to a dividend yield of 1.86%.
| Dividend Per Share | $1.45 |
| Dividend Yield | 1.86% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 70.22% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.86% |
| Earnings Yield | 2.66% |
| FCF Yield | 3.91% |
Analyst Forecast
The average price target for AstraZeneca is $87.25, which is 11.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $87.25 |
| Price Target Difference | 11.67% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 7.49% |
| EPS Growth Forecast (5Y) | 26.10% |
Stock Splits
The last stock split was on July 27, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 27, 2015 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
AstraZeneca has an Altman Z-Score of 3 and a Piotroski F-Score of 7.
| Altman Z-Score | 3 |
| Piotroski F-Score | 7 |